Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab (Q73888073)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

G A Kennedy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

J F Seymour

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

M Wolf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

H Januszewicz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

J Davison

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

C McCormack

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

G Ryan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

H M Prince

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 October 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Haematology

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

250-256

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

Alemtuzumab in T-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

Bone marrow failure associated with human herpesvirus 8 infection after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

Depressed lymphokine activated killer cell activity in mycosis fungoides. A possible marker for aggressive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

Sézary syndrome: diagnosis, prognosis, and critical review of treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

Alemtuzumab in stem cell transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

Structural motifs involved in human IgG antibody effector functions

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

The immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine production by Sézary T cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2003.00143.X

7 January 2021

10.1034/J.1600-0609.2003.00143.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12950233%20AND%20SRC:MED&resulttype=core&format=json